Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415476 | 0.91 | CA1 (0.41) | FABP7FABP5CA1CA2CPB1 | |
| SCHEMBL12415474 | 0.89 | ALDH1A1 (0.46) | FABP7FABP5CA1CA2TGM2 | |
| SCHEMBL12415464 | 0.88 | FABP7 (0.52) | FABP7FABP5CA1CA2ALDH1A1 | |
| SCHEMBL15592928 | 0.81 | CPB1 (0.42) | FABP7FABP5CA1CA2CPB1 | |
| SCHEMBL12415458 | 0.80 | FABP7 (0.43) | FABP7FABP5CA1CA2CPB1 | |
| SCHEMBL8694813 | 0.70 | FABP7 (0.50) | FABP7FABP5TGM2ALDH1A1 | |
| SCHEMBL8694810 | 0.70 | FABP7 (0.50) | FABP7FABP5TGM2ALDH1A1 | |
| SCHEMBL19323426 | 0.70 | CA1 (0.63) | FABP7FABP5CA1CA2ALDH1A1 | |
| SCHEMBL8694818 | 0.70 | FABP7 (0.50) | FABP7FABP5TGM2ALDH1A1 | |
| SCHEMBL15080034 | 0.69 | TSHR (0.61) | CA1CA2CPB1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080984-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2014-03-20 | — | — | US | disclosed |
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | ZANNA SCITECH CO., LTD. (CN) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172381-A1 | HIGHLY ACTIVE METATHESIS CATALYSTS SELECTIVE FOR ROMP AND RCM REACTIONS | RCSD1, RRP12, TIAM1 | FABP7 4747/4885FABP5 4476/4885CA1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.